Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MAP2K1

MAP2K1

Basics

Aliases:
This biomarker is also known as:
  • MAPKK1,
  • MEK 1,
  • mitogen-activated protein kinase kinase 1,
  • MAP kinase kinase 1,
  • protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1),
  • dual specificity mitogen-activated protein kinase kinase 1,
  • MEK1,
  • MAPK/ERK kinase 1,
  • PRKMK1,
  • MAPKK 1,
  • ERK activator kinase 1,
  • EC 2.7.12.2,
  • MKK1,

View in BioMuta

Description…

MAP2K1, or mitogen-activated protein kinase kinase 1, is a dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. MAP2K1 is located upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. MAP2K1 is thought to be involved in binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors, as well as cellular processes such as proliferation, differentiation, transcription regulation and development.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: MAP2K1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

MAP2K1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.